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TBE, and salmonellosis are likely to be majorly affected by climate change.
CONCLUSIONS: Accelerating climate change carries a profound threat for the in-
creased burden of infectious diseases worldwide. To attain the maximum disease
prevention, an understanding of the ecology of infectious diseases must be devel-
oped in order to protect vulnerable populations, rather than focussing on single
agent of disease.
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OBJECTIVES: To forecast and better understand the primary drivers of the inci-
dence and prevalence of andmortality from drug sensitive andmultidrug resistant
tuberculosis (DS-TB and MDR-TB, respectively).METHODS: The Tuberculosis Sim-
ulation Model (TBSM) is a dynamic disease simulation model that uses historical
and current disease incidence, treatment success rates, mortality, and transmis-
sion trends and can account for expected market events to estimate future DS-TB
and MDR-TB incidence, prevalence and mortality in China. RESULTS: The model
shows that between 2010 and 2050, DS-TB incidence, prevalence andmortality will
decrease by 29%, 52% and 29%, respectively, whereas MDR-TB incidence, preva-
lence and mortality will fall by 3%, -11% and 10%, respectively. These reductions
would be driven by an expected decrease in the pool of people with latent infection
(brought about by improved cure rates which in turn reduces transmission rates)
and reduced rate of progression from latent to active TB. CONCLUSIONS: Results
from this model demonstrate considerable anticipated decreases in DS-TB and
MDR-TB incidence and mortality in China over the next forty years; the decreases
are much larger for DS-TB than for MDR-TB. Improvements in MDR-TB diagnosis
and improved cure rates due to betterMDR-TB treatments can likewise be expected
to decrease MDR-TB incidence, prevalence and mortality over the long run. This
adaptable TBSM tool has potential value in public health practice by forecasting
outcomes of interventions and can also be useful for cost effectivenessmodeling by
country or by region by defining critical unmet need.
INFECTION - Cost Studies
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OBJECTIVES: To compare direct health care costs of treatment experienced pa-
tients with HIV/AIDS before and after triple class failure across participating
centers.METHODS: The resource use data for eligible patients were collected two
years before, and  90 days following the date of triple class failure (TCF), which
was between January 2002 and June 2008. The treatment failure was defined as
virological failure to at least one drug from each of three classes (NRTI, NNRTI and
PI). Costs of resource use at patient levelwere estimated bymultiplying the number
of resources used by the national micro-costing-based estimates. Comparisons of
log-transformed expenditure data for the first 3, 6, 12 and 24 months before TCF
with their corresponding intervals after TCF were carried out using linear mixed
model. RESULTS:Of 42 patients recruited,mean agewas 38 years andmajority was
male (66.7%). Outpatient visit expenditure after TCF was significantly 78.767.34,
78.2613.28 and 683.0090.21 baht higher than that before TCF during the first 3, 6
and 24months respectively (P0.001,0.003, and0.001, respectively). Compared
with before TCF, expenditures on direct HIV lab tests (CD4/viral load/genotyping)
after TCF were significantly 5133.74661.80, 6907.23742.23, 7505.29981.76 and
9069.931219.37 Baht higher at the first 3, 6, 12 and 24 months, respectively
(P0.001, 0.001, 0.001, and 0.004, respectively). Expenditures on antiretroviral
medications after TCFwere also higher althoughwith significance only for the first
24 months (148414.0632322.67 baht higher, P0.007) and with borderline signifi-
cance for the first 3, 6 and 12months. Finally, overall direct expenditures after TCF
were significantly higher than those before TCF in all 4 periods. CONCLUSIONS:
Once triple class failure occurred, overall direct expenditures increased signifi-
cantly as early as 3 months and through 2 years of follow-up. The most dramatic
increase was the costs associated with laboratory tests, especially genotyping, and
outpatient visits.
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OBJECTIVES: Older adults are in an increasing risk of pneumococcal diseases, in-
cluding meningitis and bacteremia (invasive pneumococcal disease, IPD), and
pneumonia. The objective of this study was to estimate the clinical and economic
burden of pneumococcal disease in adults 50 years of age in Taiwan.METHODS:
Cases of hospitalized IPD and cases of hospitalized and outpatient pneumonia
were obtained by ICD-9 codes from Taiwan’s National Health Insurance Reim-
bursement Database from 2002-2009. Pneumococcal pneumonia was assumed to
comprise 23.8% of all-cause pneumonia based on published literature. Data were
stratified by age groups 50-64, 65-74, 75-84 and 85. Average incidence rates were
calculated by dividing cases by age group and year specific population figures. Cost
was extracted from the database for inpatient and outpatient cases; mortality es-
timation was based on hospital mortality. RESULTS: The average incidence per
100,000 person years was 2.4 for IPD, 278.8 for hospitalized pneumococcal pneu-
monia, and 1376.4 for outpatient pneumococcal pneumonia. Mortality was 12.2%
for IPD and 10.0% for hospitalized pneumonia. Comparedwith adults 50-64 years of
age, the incidence of pneumococcal hospitalization were 3.7 fold higher in those
65-74, 9.7 fold higher in 75-84 and 19.5 fold higher in those 85. The total number
of hospitalizations increased by 20% from 2002 to 2009, largely attributable to pop-
ulation growth. In 2009, there were 16,711 pneumococcal hospitalizations, 103,302
outpatient visits, and 1,920 deaths, with a total cost of NT$ 2.92 billion. Hospitalized
pneumococcal pneumonia was responsible for 94% of costs and 99% of mortality.
CONCLUSIONS: The morbidity and mortality of pneumococcal disease increases
sharply with advancing age, signaling an increasing public health problem in older
adults as the population ages. Expanded utilization of cost-effective treatment and
prevention efforts are warranted to alleviate the burden of pneumococcal diseases
in Taiwan.
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OBJECTIVES: To estimate direct medical cost and productivity lost for invasive
pneumococcal diseases in child under 2 in urban China. METHODS: Six health
status contained pneumococcal meningitis (inpatient), pneumococcal septicemia
(inpatient), pneumonia (all-cause, inpatient), pneumonia (all-cause, outpatient),
mild otitis media (all-cause,outpatient) and sever otitis media (all-cause, outpa-
tient )were considered. Age-specific cost was collected from electronic patient re-
cords (2010) from 14 hospitals in 7 cities in China. 2 hospitals in each city was
selected (1 Children’s Hospital, 1 Comprehensive Hospitals) and 7 field cities in-
cluding Beijing, Guangzhou, Shenzhen, Wuhan, Xi’an, Chengdu and Shenyang
were enrolled. Directmedical cost included registry fee, medications, and diagnos-
tic tests fee, hospitalization expenditure. Cost of productivity lost were days for
work absent of patient plus time consumed of infirmaries. In first part, weighted
average method was used to calculate average direct medical cost. In second part,
daily wage rate was applied to estimate cost of productivity lost. RESULTS: The
average direct medical cost in all IPD cases (pneumococcal meningitis& pneumo-
coccal septicemia) was 20,950 Yuan (95%CI: 4,489-101,003). Average 19 working
days lost in patients’ relatives for caring and costs of productivity lost was 1934
Yuan (95%CI: 532-6,412) per patient. CONCLUSIONS: IPD has a serious impact on
life quality of child under 2 in Chinese urban areas and it could lead to severe
economic burden.
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OBJECTIVES: To analyze the inpatient direct medical costs of pneumonia among
regions, level of cities, and types of the hospitals. Difference of reimbursement rate
between the Urban Employee Basic Medical Insurance (UEBMI) and Urban Resident
Basic Medical Insurance (URBMI) plans were compared. METHODS: Systematic
sampling was used to collect data on inpatients costs of pneumonia in 2009 in
China. The database includes 2868 hospitals from 60 cities. Direct medical costs of
inpatients with pneumonia and reimbursement rate between UEBMI and URBMI
planswere analyzed. RESULTS: In 2009, pneumonia was themost frequent disease
in children below 5 years old and 5th among people 6 to 65 years old in China. In
total 210,421 hospitalization case, the average cost of inpatient pneumonia was
5,415 Yuan ($853) per patient, and the expense in capital cities, prefectural-level
cities, and county-level cities were 16,375 Yuan ($2,579), 4,321 Yuan ($681), and
4,434 Yuan ($698), respectively. The average length of hospitalizationwas 14.6 days
for patients covered with UEMBI, and 11.7 days for those covered with URMBI.
Almost 67% of the direct medical costs were covered by two medical insurance
systems, but differed by system as 73.35% for urban employees and 51.99% for
urban residents. Patients below 5 years old paid 64.76% of the direct medical costs
out of pocket, whereas people over 65 year old only paid 27.2% because they were
shielded by two different systems. CONCLUSIONS: In China, pneumonia is a com-
mon disease that mainly affects children and elderly people. There was significant
difference in directmedical costs and the length of hospitalization among different
regions and medical insurance systems. Costs in big cities were much higher than
smaller ones because of the unbalanced distribution and uneven economics situ-
ation. The reimbursement rate of URMBI was much lower than that of UEMBI.
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OBJECTIVES: Nosocomial infection can occur more frequently in patients on ad-
mission to the hospital. Patients must result in a longer treatment stays, and in-
crease costs from the use of antibiotics to treat patients. The purpose of this study
was aimed to calculate the value of antibiotics used to treat patients with nosoco-
mial infections in inpatient department at Nakhon Pathom hospital. METHODS:
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